We are live on ! Find out more
SCS

Syquant Capital SAS Portfolio holdings

AUM $447M
1-Year Est. Return 13.04%
This Fund
S&P 500
This Quarter Est. Return
+13.09%
1 Year Est. Return
+13.04%
3 Year Est. Return
+175.6%
5 Year Est. Return
+350.63%
10 Year Est. Return
–
AUM
$348M
AUM Growth
+$46.8M
Cap. Flow
+$24M
Cap. Flow %
6.88%
Top 10 Hldgs %
98.74%
Holding
27
New
13
Increased
1
Reduced
–
Closed
10

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$126M
2
K
Kellanova
K
+$29.4M
3
ETNB
89bio
ETNB
+$26.4M
4
IPG
Interpublic Group of Companies
IPG
+$22M
5
INFA
Informatica
INFA
+$13.3M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$103M
2
ESGR
Enstar Group
ESGR
+$24.2M
3
WBA
Walgreens Boots Alliance
WBA
+$14.7M
4
TGI
Triumph Group
TGI
+$14.6M
5
JNPR
Juniper Networks
JNPR
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 48.26%
2 Consumer Staples 35.62%
3 Communication Services 6.84%
4 Technology 4.9%
5 Financials 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$129M 37.01%
+1,208,312
New +$126M
K
2
DELISTED
Kellanova
K
$124M 35.62%
1,513,343
+369,775
+32% +$29.4M
ETNB
3
DELISTED
89bio
ETNB
$38.1M 10.94%
+2,593,694
New +$26.4M
IPG
4
DELISTED
Interpublic Group of Companies
IPG
$23.8M 6.84%
+854,279
New +$22M
INFA
5
DELISTED
Informatica
INFA
$13.4M 3.83%
+537,775
New +$13.3M
CEPF
6
Cantor Equity Partners IV
CEPF
$597M
$5.09M 1.46%
+500,000
New +$5.08M
WNS
7
DELISTED
WNS Holdings
WNS
$3.71M 1.07%
+48,659
New +$3.64M
CRH icon
8
CRH
CRH
$68.8B
$2.86M 0.82%
+23,820
New +$2.52M
MBVIU
9
M3-Brigade Acquisition VI Corp Units
MBVIU
$309M
$2.02M 0.58%
+200,000
New +$2.01M
AEXA
10
American Exceptionalism Acquisition Corp
AEXA
$575M
$1.37M 0.39%
+125,000
New +$1.35M
PACHU
11
Pioneer Acquisition I Corp Units
PACHU
$1.11M 0.32%
110,000
– –
MRUS
12
DELISTED
Merus
MRUS
$1.1M 0.32%
+11,691
New +$762K
WENNU
13
Wen Acquisition Corp Unit
WENNU
$261K 0.07%
25,000
– –
BLZRU
14
Trailblazer Acquisition Corp Unit
BLZRU
$256K 0.07%
+25,000
New +$253K
BCSS.U
15
Bain Capital GSS Investment Corp Units
BCSS.U
$202K 0.06%
+20,000
New +$202K
ONCHU
16
1RT Acquisition Corp Units
ONCHU
$156M
$105K 0.03%
+10,000
New +$105K
APP icon
17
Applovin
APP
$143B
– –
-7,180
Closed -$2.51M
BPMC
18
DELISTED
Blueprint Medicines
BPMC
– –
-805,603
Closed -$103M
DNB
19
DELISTED
Dun & Bradstreet
DNB
– –
-1,248,800
Closed -$11.4M
ESGR
20
DELISTED
Enstar Group
ESGR
– –
-71,807
Closed -$24.2M
JNPR
21
DELISTED
Juniper Networks
JNPR
– –
-302,620
Closed -$12.1M
SKX
22
DELISTED
Skechers
SKX
– –
-183,934
Closed -$11.6M
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
– –
-247,000
Closed -$11.6M
TGI
24
DELISTED
Triumph Group
TGI
– –
-568,177
Closed -$14.6M
WBA
25
DELISTED
Walgreens Boots Alliance
WBA
– –
-1,284,217
Closed -$14.7M
1
2

Similar funds

PT
Plimoth Trust Plymouth, Massachusetts $447M AUM 24.12% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $448M AUM 21.79% 1-Year Est. Return
PC
Peavine Capital Reno, Nevada $446M AUM 7.66% 1-Year Est. Return
AIS
American Investment Services Great Barrington, Massachusetts $448M AUM 21.7% 1-Year Est. Return
SCA
Stokes Capital Advisors Greenwood, South Carolina $446M AUM 13.55% 1-Year Est. Return
FTA
Financial & Tax Architects St Louis, Missouri $448M AUM 13.98% 1-Year Est. Return
GC
Guidance Capital Lousville, Kentucky $446M AUM 19.83% 1-Year Est. Return
POEH
Post Oak Energy Holdings Houston, Texas $449M AUM 53.94% 1-Year Est. Return

Syquant Capital SAS's Q3 2025 Portfolio in Review

As of Q3 2025, Syquant Capital SAS held 27 positions worth $348M, up 16% from $302M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Syquant Capital SAS deployed $24M of net new capital in Q3 2025, opening 13 new positions and adding to 1 existing holding. Its largest new stake was Verona Pharma: 1,208,312 shares worth $129M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Consumer Staples and Communication Services.

On the sell side, the most notable exit was Blueprint Medicines, an estimated $103M sold.

  • Syquant Capital SAS's largest Q3 2025 buy was Verona Pharma: 1,208,312 shares worth $129M.
  • Syquant Capital SAS added most to Kellanova in Q3 2025, an estimated $29.4M increase.
  • Syquant Capital SAS fully exited Blueprint Medicines in Q3 2025, selling an estimated $103M.
  • Syquant Capital SAS's ten largest holdings make up 99% of its $348M portfolio in Q3 2025.
  • Syquant Capital SAS opened 13 new positions and closed 10 in Q3 2025.
  • Syquant Capital SAS's portfolio value rose 16% quarter-over-quarter to $348M.

Based on Syquant Capital SAS's 13F filing for Q3 2025, filed 28 Oct 2025.